Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03494205
Other study ID # 211820931
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 2, 2018
Est. completion date February 10, 2022

Study information

Verified date May 2022
Source University of Bern
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized controlled trial comparing Urtica comp. gel (Swissmedic listed medication in the category of "Anthroposophic Medication without Indication") against standard skin care, examining its effect in prevention and treatment of radiation dermatitis in breast cancer patients under Radiation therapy.


Description:

Radiation dermatitis is one of the most common side effects of radiotherapy for cancer and affects around 95 % of patients receiving radiotherapy. Patients with breast cancer as well as patients with head and neck cancer are most frequently affected, due to the higher radiation dose to the skin, as compared to other cancer types. Radiation dermatitis has a profound impact on the quality of a patient's life, due to pain and discomfort. Skin lesions bear a marked risk of infection. In addition, all these issues may be the cause of interruption of radiation therapy, resulting in inadequate disease treatment. Despite a plentitude of studies researching local and systemic therapeutic approaches, currently no treatment (aside from local steroids which bear substantial side-effects) can be explicitly recommended. Thus, further research, especially in therapeutic options with a positive side-effect spectrum would be highly beneficial. Urtica comp. gel is a Swissmedic registered medication. It is e.g. applied in first and second-degree burn and scalding as well as sunburn and has been used in over 80 years with an excellent safety profile. Positive clinical experience in treating radiation dermatitis with Urtica comp. gel suggest studying this therapeutic option in a pilot trial.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date February 10, 2022
Est. primary completion date February 10, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Radiation therapy for Breast Cancer - Age >= 18 years - Written informed consent Exclusion Criteria: - Ulcerated cancer at beginning of radiation therapy - Skin lesions in the radiation area before start of radiation therapy - Known allergies, hypersensitivity or reactions against one of the constituents of the investigational product [5] - Any neurological or psychiatric conditions that, in the evaluation of the treating physician, deem the patient incapable to participate in the study - Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) as judged by the PI The following criteria are exclusion criteria for the conduct of the radiation therapy, which is prerequisite for inclusion into the study. Thus, such patients will anyway not meet the inclusion criteria and are explicitly excluded from participation: - Women who are pregnant or breast feeding - Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. - Please note that female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Urtica comp. gel
Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light. It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers.
institutional standard skin care "Excipial-Hydrolotion"
The institutional standard skin care "Excipial-Hydrolotion" is available to all patients

Locations

Country Name City State
Switzerland Universitätsklinik für Radio-Onkologie Bern

Sponsors (1)

Lead Sponsor Collaborator
University of Bern

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Radiation Dermatitis (RD) measured by the CTCAE Comparison between both arms During the whole study (six weeks of therapy plus follow-up of six weeks)
Primary Severity of RD measured by the CTCAE Comparison between both arms During the whole study (six weeks of therapy plus follow-up of six weeks)
Secondary Percentage of patients requiring no additional therapy for RD (e.g. Flammazine or Ialugen plus) Comparison between both arms measuring the use of Flammazine or Ialugen plus (rescue-care) During the whole study (six weeks of therapy plus follow-up of six weeks)
Secondary Percentage of patients RD free at end of therapy (EOT) measured by the CTCAE Comparison between both arms EOT (=time point specifically at end of 6 weeks of radiation therapy)
Secondary Percentage of patients with secondary skin infection / need of topical and systemic antibiotics Comparison between both arms During the whole study (six weeks of therapy plus follow-up of six weeks)
Secondary Patients quality of life measured by the Skindex Comparison between both arms. During the whole study (six weeks of therapy plus follow-up of six weeks)
Secondary Patients evaluation of the treatment (satisfaction) measured by the FACIT-TS-G (total scale) Comparison between both arms. The FACIT-TS-G (Functional Assessment of Chronic Illness Therapy treatment satisfaction - General) assesses the patients treatment satisfaction at the end of therapy (EOT after 6 weeks of Radiation therapy).
The questionnaire consists of 8 questions, 3 of which are answered on a scale ranging from 0 (much worse) to 4 (much better), 3 questions ranging from 0 (not al all) to 3 (totally) and two questions which can be answered with 0 (no), 1(maybe) and 2 (yes). Thus on all scales a higher value represents a better outcome. The total score range is 0 (not satisfied at all) to 25 (highly satisfied).
EOT (=time point specifically at end of 6 weeks of radiation therapy)
Secondary Patients evaluation of the treatment (Skin condition) measured by visual analog scale (VAS) with the Skin Condition VAS the patient self-assesses the skin condition in the radiation area.
The questionnaire consists of 5 subscales: pain, itching, burning, irritation, visual appearance. Each scale ranges from 0 (not apparent) to 100 (worst possible expression). For the total score all values are summed up and divided by 5 (number of scales) resulting in a total score ranging from 0 (best possible outcome = no skin affection due to radiation) to 100 (worst possible outcome).
During the whole study (six weeks of therapy plus follow-up of six weeks)
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Not yet recruiting NCT06040983 - Clinical Investigation on the Treatment of Radiation Induced Dermatitis With FR-101 Chest Dressing N/A
Withdrawn NCT05505214 - Topical Steroids & Bacterial Decolonization for Radiation Dermatitis Phase 2
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Completed NCT05450848 - StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis N/A
Active, not recruiting NCT05594498 - A Study of StrataXRT in the Prevention of Radiation Dermatitis in Breast Cancer Patients N/A
Recruiting NCT04110977 - A Reminder App to Reduce Radiation Dermatitis Rates in Patients With Head-and-Neck Cancer N/A
Recruiting NCT06158347 - Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients With Localized Breast Cancer N/A
Recruiting NCT05553392 - StrataXRT Versus Aquaphor for the Prevention and Management of Radiation Dermatitis N/A
Active, not recruiting NCT04268056 - Characterization of Skin Microbiome Profile and it's Correlation to Radiation Dermatitis
Not yet recruiting NCT04888234 - Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis. Phase 2
Terminated NCT01597921 - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer N/A
Completed NCT00481884 - Comparing RadiaPlexRx Hydrogel and Standard-of-Care for Radiation Dermatitis in Breast Cancer Patients Phase 3
Completed NCT05810194 - Retrospective Cohort Study Comparing a Novel Gel Dressing vs SoC in the Treatment of Radiation Dermatitis
Completed NCT03941665 - Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients N/A
Not yet recruiting NCT02051907 - Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis Phase 2
Completed NCT02839473 - Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial Phase 3
Completed NCT00573365 - LED Photomodulation for Prevention of Post-Radiation Treatment Dermatitis N/A
Completed NCT00876642 - Trial Comparing Best Supportive Care to Aloe Vera Gel Phase 3
Completed NCT03910595 - Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients N/A